RFP
NTLA icon

Root Financial Partners’s Intellia Therapeutics NTLA Stock Holding History

Root Financial Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.73K Buy
+291
New +$3.71K ﹤0.01% 2063

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Root Financial Partners's NTLA Position: Q1 2026 in Review

Root Financial Partners opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 291 shares worth $3.73K. The stake represents ﹤0.01% of the portfolio and ranks #2063 among its holdings.

303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Root Financial Partners held 291 shares of Intellia Therapeutics worth $3.73K as of Q1 2026.
  • Intellia Therapeutics was a new Root Financial Partners position in Q1 2026.
  • Intellia Therapeutics made up ﹤0.01% of Root Financial Partners's portfolio in Q1 2026, its #2063 holding.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Root Financial Partners's 13F filing for Q1 2026, filed 24 Apr 2026.